The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a study of the oral inhibitor PTC299 on tumor VEGF synthesis.
J. J. Luke
Research Funding - PTC Therapeutics
L. A. Callahan
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
C. H. Darby
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
E. Moss
Research Funding - PTC Therapeutics
J. Winkelman
Research Funding - PTC Therapeutics
J. Barth
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
G. L. Elfring
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
A. Ogden
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
G. K. Schwartz
Research Funding - PTC Therapeutics
M. M. Gounder
Research Funding - PTC Therapeutics